Recital 89, Decision_act (EU) 2004/104

In forcesince 27 Nov 2002

Merck states, "At least since the end of the 1980s, there were contacts between Merck and Aventis with respect to MG, whose primary goal was to maintain the status quo of the respective 50 % market shares of both companies on the worldwide MG market and to increase the price of MG. An additional goal strived for was to prevent, if possible, a switch by their respective customers from one to the other supplier"(57). In a different sentence Merck states, "To prevent switches, it was agreed that each party would respond to a price query from a customer of the other by quoting the list price"(58).